Is Sermorelin Legal in Massachusetts?

The Short Answer: Sermorelin Is Conditionally Legal in Massachusetts

Sermorelin is not a controlled substance in Massachusetts and is not banned under state pharmacy law. A Massachusetts-licensed physician, nurse practitioner, or physician assistant can write a lawful prescription for it today. The condition is that the prescription must be filled by a compounding pharmacy operating under federal 503A or 503B standards, because no FDA-approved finished sermorelin product currently exists for general clinical use.

The nuance matters. Several peptides, including BPC-157 and TB-500, have been placed on the FDA's list of bulk drug substances that may not be compounded, effectively removing them from lawful clinical use. Sermorelin has not been placed on that prohibitive list, but its regulatory future is not guaranteed. Patients and clinicians should track FDA guidance updates at least annually.

Why "Conditional" Matters

The word conditional reflects two layers of law operating simultaneously. Federal law governs what a compounding pharmacy may legally prepare. State law governs who may prescribe and what the pharmacy must do to comply with the Massachusetts Board of Registration in Pharmacy. Both layers must be satisfied for a sermorelin prescription to be lawful.

Failing either layer exposes the prescriber, the pharmacy, and potentially the patient to regulatory or legal liability. A prescription written by a licensed clinician but filled by an unregistered offshore pharmacy, for example, is unlawful regardless of what Massachusetts state law permits.

Federal Legal Framework: FDA, Compounding, and the Bulk Drug List

Sermorelin acetate was originally approved by the FDA as Geref Diagnostic (Serono) for stimulating growth-hormone release in the evaluation of pituitary function. That product was voluntarily withdrawn from the US market in 2008 for commercial, not safety, reasons. [1] Because no currently marketed finished drug product contains sermorelin, pharmacies cannot simply copy an approved formulation. They must compound it under one of two federal pathways.

503A Compounding Pharmacies

Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act) permits state-licensed compounding pharmacies to prepare drug products for individual patients when a valid prescription exists. [2] Key requirements include:

• The substance must not appear on the FDA's list of bulk drug substances that may not be compounded (the "Category 2" or "do-not-compound" list).
• The compounded product must not be essentially a copy of a commercially available finished drug.
• The pharmacy must comply with applicable USP standards (USP 797 for sterile preparations).

Sermorelin currently appears on the FDA's list of nominated bulk drug substances under evaluation (Category 1), meaning it has been nominated for possible inclusion on the list of substances that may be compounded, but a final determination has not been issued. [3] That status allows 503A pharmacies to continue compounding it while the FDA's review is pending, though clinicians should verify current status before prescribing.

503B Outsourcing Facilities

Section 503B of the FD&C Act creates a category of registered outsourcing facilities that may produce larger batches without individual patient prescriptions, subject to FDA oversight and current good manufacturing practice (cGMP) requirements. [4] A 503B facility may compound sermorelin for office use or distribution to healthcare providers, provided the substance is not on the prohibited list and the facility is FDA-registered.

The FDA publishes a current list of registered 503B outsourcing facilities. [5] Patients obtaining sermorelin from a telehealth provider should confirm the dispensing pharmacy appears on that list or holds a valid 503A state license.

The FDA's Bulk Drug Substances Scrutiny

The FDA has increased enforcement against unapproved peptides since 2023. The agency's Guidance for Industry on Outsourcing Facility Compounding of Drug Products explicitly states that bulk drug substances used in compounding must meet identity, strength, quality, and purity standards. [6] The FDA has also issued warning letters to compounding pharmacies dispensing peptides without adequate quality controls.

Sermorelin's continued availability depends on the FDA not moving it to the do-not-compound list. Clinicians at HealthRX monitor the FDA's bulk drug substances database quarterly to confirm ongoing permissibility.

Massachusetts State Legal Framework

Massachusetts does not schedule sermorelin under Massachusetts General Laws (MGL) Chapter 94C, the Controlled Substances Act. [7] It is not listed in any Massachusetts Department of Public Health scheduling notice as of the date of this review. That means possessing sermorelin pursuant to a valid prescription carries no state criminal exposure under Chapter 94C.

Massachusetts Board of Registration in Pharmacy

The Massachusetts Board of Registration in Pharmacy regulates all pharmacy practice in the state, including compounding. The Board has adopted rules aligned with USP 797 (sterile compounding) and requires that compounding pharmacies dispensing to Massachusetts patients hold a valid Massachusetts pharmacy license or a reciprocal non-resident pharmacy permit. [8]

A patient in Boston receiving sermorelin from an out-of-state 503A pharmacy is protected provided that pharmacy holds a Massachusetts non-resident pharmacy license. Patients should request proof of licensure before filling any compounded prescription.

Massachusetts Medical Practice Act

The Board of Registration in Medicine governs prescribing under MGL Chapter 112. Prescribing sermorelin is lawful when the prescriber:

1. Holds an active Massachusetts license.
2. Establishes a valid patient-provider relationship (which may be done via telehealth under Massachusetts law [9]).
3. Documents clinical indication, history, and informed consent in the medical record.
4. Issues the prescription through a pharmacy that meets federal compounding standards.

No Massachusetts regulation specifically restricts growth hormone secretagogues or GHRH analogs to subspecialty prescribers. A primary care physician, internist, or endocrinologist may prescribe sermorelin within their scope of practice.

Telehealth Prescribing in Massachusetts

Massachusetts expanded telehealth prescribing rights under the Act Advancing Telehealth Services (2022). [9] A Massachusetts-licensed clinician may conduct an initial consultation via synchronous video and issue a lawful sermorelin prescription without an in-person visit, provided the standard of care requirements for history-taking, physical examination (or documentation of why one was deferred), and informed consent are met. Controlled substances still require in-person visits under DEA rules, but sermorelin is not a controlled substance, so that restriction does not apply.

Clinical Background: What Is Sermorelin and Why Is It Prescribed?

Sermorelin acetate is a synthetic 29-amino-acid analog of endogenous growth hormone-releasing hormone (GHRH 1-29). It binds the GHRH receptor on anterior pituitary somatotrophs, stimulating pulsatile growth hormone (GH) secretion. [10] Because it amplifies the body's own GH pulse rather than replacing GH directly, it preserves the hypothalamic-pituitary feedback axis.

Growth Hormone Decline and Clinical Indication

GH secretion declines approximately 14% per decade after age 30. [11] Adults with confirmed GH deficiency experience reduced lean mass, increased visceral adiposity, impaired bone mineral density, and reduced quality of life. The Endocrine Society's 2019 Clinical Practice Guideline on Growth Hormone Deficiency in Adults recommends GH replacement for patients with confirmed GHD, defined by peak GH <3 mcg/L on a stimulation test (or <5 mcg/L with two additional pituitary hormone deficiencies). [12]

Sermorelin is used as an alternative to recombinant human GH (rhGH) in patients with intact pituitary function. Rather than replacing GH, it stimulates endogenous release. This distinction matters clinically: the feedback axis remains intact, reducing the risk of GH excess compared with exogenous rhGH administration.

Typical Dosing

Clinical compounding protocols commonly use 200 to 500 mcg of sermorelin acetate injected subcutaneously once nightly. The nighttime timing mirrors the natural GH pulse that occurs during slow-wave sleep. [10] Dosing is individualized based on baseline IGF-1, symptom burden, and tolerance. Labs are typically rechecked at 6 and 12 weeks after initiation.

Evidence Base

A randomized, double-blind, placebo-controlled study published in the Journal of Clinical Endocrinology and Metabolism (N=226 older adults) showed that GHRH analog administration over 6 months significantly increased IGF-1 levels (P<0.001) and lean body mass compared with placebo. [13] A separate analysis found that GHRH stimulation improved sleep architecture, increasing slow-wave sleep duration by roughly 20% in older men with age-related GH decline. [14]

The data on body composition are promising but not definitive for the general anti-aging population. The Endocrine Society guideline explicitly cautions against prescribing GH or GH secretagogues solely for anti-aging purposes in non-GHD adults, citing insufficient long-term safety data. [12]

How to Get Sermorelin in Massachusetts

Getting a lawful sermorelin prescription in Massachusetts requires three things: a clinical evaluation by a licensed Massachusetts provider, laboratory testing to establish indication, and a pharmacy that meets federal compounding standards.

Step 1: Clinical Evaluation

The evaluation should include:

• Comprehensive history (symptoms of GH deficiency, prior pituitary disease, malignancy history)
• Physical examination or documented telehealth assessment
• Baseline labs: serum IGF-1, fasting glucose, HbA1c, comprehensive metabolic panel, thyroid function, and (for men) testosterone

IGF-1 is the primary screening biomarker for GH axis function. A value below the age- and sex-adjusted reference range supports clinical use of a GHRH secretagogue. [12]

Step 2: GH Stimulation Testing (When Indicated)

The Endocrine Society guideline recommends formal GH stimulation testing to confirm GHD in adults without a clear cause (e.g., no history of pituitary surgery or radiation). The glucagon stimulation test and the insulin tolerance test are both accepted standards. [12] Not every compounding protocol requires formal stimulation testing for low-normal IGF-1 in older adults, but documentation of clinical rationale is required for defensible prescribing.

Step 3: Choosing a Compliant Pharmacy

Massachusetts patients should verify:

1. The compounding pharmacy holds a valid Massachusetts pharmacy license or non-resident permit.
2. The facility is either an FDA-registered 503B outsourcing facility [5] or a 503A pharmacy that compounds sermorelin under USP 797.
3. The pharmacy provides a certificate of analysis (CoA) from a third-party laboratory confirming identity, potency, and sterility for each lot.

Requesting a CoA is not excessive due diligence. The FDA's own inspection data show that sterility failures in compounded sterile preparations are the most common critical deficiency cited in Form 483 observations. [6]

Step 4: Ongoing Monitoring

After starting sermorelin, standard monitoring includes:

• IGF-1 at 6 and 12 weeks, then every 6 months
• Fasting glucose at 3 months (GH can induce insulin resistance at supraphysiologic levels)
• Subjective symptom review: sleep quality, energy, recovery, body composition

Dose adjustments are guided by IGF-1 response and symptom burden, with a target IGF-1 in the upper-normal range for the patient's age and sex.

Risks, Contraindications, and Informed Consent

Sermorelin is generally well tolerated. The most common adverse effects reported in clinical studies are injection-site reactions (erythema, pain), transient facial flushing, and headache. [10] More clinically significant concerns include:

Glucose metabolism. GH opposes insulin. Supraphysiologic GH stimulation can impair glucose tolerance. Patients with type 2 diabetes or prediabetes (fasting glucose >100 mg/dL) require more frequent glucose monitoring. The American Diabetes Association Standards of Care note that GH and IGF-1 axis dysregulation affects glucose homeostasis. [15]

Active malignancy. GH and IGF-1 are mitogenic. Sermorelin is contraindicated in patients with active malignancy or a history of GH-sensitive tumors (e.g., certain pituitary adenomas). The Endocrine Society guideline states: "GH should not be prescribed for patients with active malignancy." [12] That caution extends by clinical consensus to GHRH analogs.

Hypothyroidism. Adequate thyroid function is necessary for GH axis response. Uncontrolled hypothyroidism blunts IGF-1 response to sermorelin. Thyroid status should be optimized before initiation.

Informed consent documentation should cover the off-label compounded status of the medication, the monitoring requirements, the absence of long-term randomized controlled trial data in non-GHD populations, and the potential for regulatory status changes.

What About Online Pharmacies and "Research Chemical" Sources?

Some websites sell sermorelin labeled "for research use only" and ship it without a prescription. This is unlawful. The FDA has issued warning letters to companies selling peptides in this manner, noting that the products are unapproved new drugs and that the "research use" label does not exempt them from the FD&C Act's drug approval requirements. [16]

Purchasing sermorelin from a non-pharmacy source, a foreign vendor, or a website that does not require a prescription exposes the buyer to products of unknown potency and sterility. It may also constitute unlawful importation under 21 U.S.C. § 331. Massachusetts residents should obtain sermorelin only through the prescription pathway described above.

Sermorelin vs. Other GHRH Peptides: A Regulatory Comparison

| Peptide | FDA Do-Not-Compound List | Massachusetts Scheduling | Notes | |---|---|---|---| | Sermorelin | Not listed (under review) | Not scheduled | Compoundable under 503A/503B pending FDA review | | CJC-1295 | Not listed | Not scheduled | Longer half-life analog; less clinical data | | Ipamorelin | Not listed | Not scheduled | GHRP, not GHRH; often combined with sermorelin | | BPC-157 | Category 2 (prohibited) | Not scheduled | Cannot be lawfully compounded for humans | | TB-500 | Category 2 (prohibited) | Not scheduled | Cannot be lawfully compounded for humans | | Tesamorelin | FDA-approved (Egrifta) | Not scheduled | Approved for HIV-associated lipodystrophy only |

This table reflects the FDA bulk drug substances database as reviewed in January 2025. [3] Statuses can change. Clinicians should verify before prescribing.